Srikant Datar

Biography

Mr. Datar has been the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University since 1996 and the Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, he was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of Novartis AG, a multinational pharmaceutical and consumer health products company, ICF International, Inc., a management, technology and policy consulting firm, and T-Mobile US, Inc., a provider of wireless voice, messaging and data services. Dr. Datar has an extensive background in accounting and finance and a variety of other business areas, including organization design and performance measurement. His strong academic and business background and his experience on the board committees of other companies allow him to make significant contributions to our Board. His service on the boards of global companies involved in pharmaceuticals and high tech gives him great insights on assessing our technology and strategies to expand our business globally. Mr. Datar has been the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University since 1996 and the Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, he was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of Novartis AG, a multinational pharmaceutical and consumer health products company, ICF International, Inc., a management, technology and policy consulting firm, and T-Mobile US, Inc., a provider of wireless voice, messaging and data services. Dr. Datar has an extensive background in accounting and finance and a variety of other business areas, including organization design and performance measurement. His strong academic and business background and his experience on the board committees of other companies allow him to make significant contributions to our Board. His service on the boards of global companies involved in pharmaceuticals and high tech gives him great insights on assessing our technology and strategies to expand our business globally.

Research Interest

pharma